Innsbruck

• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Not authorised
  2022-501389-23-00 4 end-stage renal disease or otherwise an insufficient kidney function
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 5 Locally Advanced or Metastatic Cholangiocarcinoma
• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
• A one-year study to assess if Xanomeline/Trospium (XT) can improve cognitive function in adults living with schizophrenia. Not authorised
  2025-523060-20-00 5 Schizophrenia
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Stroke in childhood due to inflammatory narrowing of blood vessels: Treatment with steroids Pending
  2022-500631-36-00 5 Focal cerebral arteriopathy and childhood stroke Focal cerebral arteri
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Pending
  2022-501389-23-02 4 end-stage renal disease or otherwise an insufficient kidney function
• A research study on how well cagrilintide and CagriSema work in children and adolescents with excess body weight Pending
  2023-509176-42-00 11 Obesity and T2D
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• Prospective analysis of the therapeutic efficacy of iron isomaltoside in combination with or without dopaminergic therapy in patients with r … Pending
  2024-512117-40-00 5 restless leg syndrome
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R … Pending
  2024-513445-37-00 5 previously untreated RT, irrespective of risk factors and disease stag
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• Daratumumab in Combination with Carfilzomib, Pomalidomide and Dexamethasone in patients with myeloma induced acute renal failure Pending
  2024-514702-31-00 4 Multiple myeloma
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O … Pending
  2024-516327-14-00 4 Ovarian cancer
• EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation Pending
  2024-518508-31-00 6 High risk atrial fibrillation patients with previous intracranial hemo
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de no … Pending
  2025-520641-69-00 4 Kidney disease
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis

Showing 1–24 of 347 trials